Chief Financial Officer (CFO)
Johnson Shun-Pong Lau
Johnson Shun-Pong Lau is a highly experienced financial executive with over 20 years of expertise in corporate finance, auditing, and financial management across public companies and a Big 4 accounting firm. As Chief Financial Officer of SL Bio, he is responsible for overseeing financial strategy, investor relations, audit processes, and operational efficiency to support the company’s growth in immunotherapy innovation. He has extensive experience in IPO preparation, financial modeling, internal controls, and multinational corporate governance, having led finance functions for U.S., U.K., and Hong Kong-listed companies and successfully managed public offerings, M&A transactions, and corporate restructuring. Prior to joining SL Bio, he held CFO roles at Beauty Express Group, Steering Holdings, China Golden Classic Group, and Sgoco Group, driving financial strategy and regulatory compliance. A Certified Practising Accountant (CPA, Aust.) and Fellow of the Hong Kong Institute of CPAs (FCPA), he holds a Bachelor of Commerce in Accounting from Monash University and is fluent in English, Mandarin, and Cantonese.
Academic Excellence
Bachelor of Commerce, Accounting, Monash University, Melbourne, Australia
Professional Achievements
With over 20 years of leadership in corporate finance, Johnson has successfully led multiple companies through IPOs, M&A transactions, and corporate restructuring across U.S., U.K., and Hong Kong-listed firms. He has played a pivotal role in enhancing financial efficiency, implementing internal controls, and driving investor relations, securing significant funding and strategic partnerships. His expertise in risk management, regulatory compliance, and multinational financial operations has positioned organizations for sustained growth and market expansion, making him a key asset in SL Bio’s mission to advance cutting-edge immunotherapies.
Professional Experience
Future FinTech Group, Inc. (formerly known as SkyPeople Fruit Juice Inc., listed on NASDAQ) – Ticker: FTFT (2014 – 2024)
Winshine Science Company Ltd. (listed on Main Board of HKEx) – Ticker: 0209.HK (2017 – 2019)
Lizhan Environmental Corporation (listed on NASDAQ) – Ticker: LZEN (2010 – 2013)
HaiKe Chemical Group Ltd. (listed on UK AIM) – Ticker: HAIK.L (2009 – 2010)
Vision and Leadership
Bringing over two decades of experience in corporate finance, IPO execution, and multinational financial management, he leads with strategic foresight, risk management, and strong financial governance. Johnson's leadership is defined by a commitment to transparency, regulatory compliance, and efficiency, ensuring that SL Bio is well-positioned for future growth. By fostering cross-functional collaboration and implementing robust financial frameworks, he is dedicated to accelerating innovation, expanding partnerships, and maximizing value for both stakeholders and patients worldwide.
